On July 10, 2025, Goldman Sachs initiated coverage on Neurocrine Biosciences (NBIX, Financial) with a "Buy" rating. The announcement was made by analyst Corinne Johnson, who set a price target of $182.00 USD for the stock.
Neurocrine Biosciences (NBIX, Financial), listed on NASDAQ, is receiving significant attention following this positive endorsement from the well-regarded investment firm. The current price target represents a positive outlook, although previous targets have not been disclosed.
This move by Goldman Sachs positions Neurocrine Biosciences (NBIX, Financial) favorably among investors seeking growth opportunities, emphasizing confidence in the company's potential. Investors and market watchers will be closely monitoring NBIX for further developments following this coverage initiation.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 23 analysts, the average target price for Neurocrine Biosciences Inc (NBIX, Financial) is $158.40 with a high estimate of $192.00 and a low estimate of $115.00. The average target implies an upside of 18.64% from the current price of $133.51. More detailed estimate data can be found on the Neurocrine Biosciences Inc (NBIX) Forecast page.
Based on the consensus recommendation from 26 brokerage firms, Neurocrine Biosciences Inc's (NBIX, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Neurocrine Biosciences Inc (NBIX, Financial) in one year is $195.83, suggesting a upside of 46.68% from the current price of $133.51. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Neurocrine Biosciences Inc (NBIX) Summary page.
